IM Cannabis (IMCC) Stock Price, News & Analysis

Company Overview

IM Cannabis Corp. is an Israel-based cannabis company focused on the research, development and commercialization of medicinal cannabis products. The company’s core operations span the cultivation of pharmaceutical-grade cannabis, the extraction of key cannabinoids and the formulation of a range of delivery systems, including oils, sprays and concentrates. Through proprietary cultivation protocols and an emphasis on analytical testing, IM Cannabis seeks to ensure consistency, purity and efficacy across its product portfolio.

In addition to cultivation, IM Cannabis invests heavily in research and development, leveraging partnerships with academic institutions and in-house laboratories to advance its cannabinoid science. The company’s R&D efforts encompass strain genetics, extraction technologies and novel formulations designed to optimize therapeutic outcomes. IM Cannabis holds a number of intellectual property assets related to extraction processes and cannabinoid enrichment techniques, positioning it to address evolving medical and wellness markets.

IM Cannabis operates through licensed facilities in Israel and Europe, with cultivation and processing sites in key markets including Spain and Portugal. The company is pursuing strategic entry into additional European markets such as Germany and Poland, supported by local distribution agreements and regulatory approvals. IM Cannabis’s international footprint is underpinned by its Precann subsidiary in Europe and IMC Laboratories in Israel, enabling cross-border product development and market expansion.

Founded in 2013, IM Cannabis has grown from a boutique cultivation enterprise into a diversified cannabis player listed on the NASDAQ under the ticker IMCC. The management team brings extensive experience from pharmaceutical and agricultural sectors, led by CEO Danny Limor and a board comprised of industry veterans. As regulatory landscapes evolve, IM Cannabis continues to refine its product offerings and expand its geographic reach, with a focus on delivering high-quality, research-driven cannabis solutions for patients and consumers worldwide.

Key Stats

• Today's Range: $2.76 to $3.37
• 50-Day Range: $1.50 to $5.22
• 52-Week Range: $1.29 to $7.12
• Volume: 100,482 shs
• Average Volume: 97,131 shs
• Market Capitalization: $11.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IM Cannabis Stock Analysis - MarketRank™

IM Cannabis scored higher than 3% of companies evaluated by MarketBeat, and ranked 936th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for IM Cannabis.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IM Cannabis is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IM Cannabis is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IM Cannabis has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.28% of the float of IM Cannabis has been sold short.

Short Interest Ratio / Days to Cover

IM Cannabis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IM Cannabis has recently increased by 100.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IM Cannabis does not currently pay a dividend.

Dividend Growth

IM Cannabis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.28% of the float of IM Cannabis has been sold short.

Short Interest Ratio / Days to Cover

IM Cannabis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IM Cannabis has recently increased by 100.99%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.63

News Sentiment

IM Cannabis has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for IM Cannabis this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for IMCC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IM Cannabis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.91% of the stock of IM Cannabis is held by insiders.

Percentage Held by Institutions

Only 7.68% of the stock of IM Cannabis is held by institutions.

IMCC Stock Analysis - Frequently Asked Questions

How have IMCC shares performed this year?

IM Cannabis' stock was trading at $2.33 at the beginning of 2025. Since then, IMCC stock has increased by 24.9% and is now trading at $2.91.

How were IM Cannabis' earnings last quarter?

IM Cannabis Corp. (NASDAQ:IMCC) announced its quarterly earnings results on Thursday, May, 15th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.31. The business had revenue of $8.69 million for the quarter, compared to analysts' expectations of $11.45 million. IM Cannabis had a negative trailing twelve-month return on equity of 122.96% and a negative net margin of 9.10%.
Read the conference call transcript.

When did IM Cannabis' stock split?

Shares of IM Cannabis reverse split before market open on Friday, July 12th 2024.The 1-6 reverse split was announced on Friday, July 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of IM Cannabis?

Shares of IMCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IM Cannabis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IM Cannabis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), GE Aerospace (GE) and AppLovin (APP).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCC
• CIK: 1792030
• Web: www.imcannabis.com
• Phone: 972-54-433-1111
• Fax: N/A
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.72 million
• Net Margins: -9.10%
• Pretax Margin: -11.97%
• Return on Equity: -122.96%
• Return on Assets: -11.69%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 0.72
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: $39.44 million
• Price / Sales: 0.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.03 per share
• Price / Book: 2.83

Miscellaneous

• Outstanding Shares: 4,040,000
• Free Float: 3,806,000
• Market Cap: $11.76 million
• Optionable: Not Optionable
• Beta: 2.19